Evidence map›Paper›PMID 39045029›Full record

ArticleMolecular therapy. Oncology2024

Combining the constitutive TRAIL-secreting induced neural stem cell therapy with the novel anti-cancer drug TR-107 in glioblastoma.

Morrent Thang, Clara Mellows, Lauren E Kass, Sabrina Daglish, Emily M J Fennell, Breanna E Mann, Alison R Mercer-Smith, Alain Valdivia, Lee M Graves, Shawn D Hingtgen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Morrent ThangNeuroscience Center, University of North Carolina-Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Clara MellowsDivision of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina-Chapel Hill School of Pharmacy, Chapel Hill, NC, USA.
Lauren E KassDivision of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina-Chapel Hill School of Pharmacy, Chapel Hill, NC, USA.
Sabrina DaglishDepartment of Pharmacology, University of North Carolina-Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Emily M J FennellDepartment of Pharmacology, University of North Carolina-Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Breanna E MannDivision of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina-Chapel Hill School of Pharmacy, Chapel Hill, NC, USA.
Alison R Mercer-SmithDivision of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina-Chapel Hill School of Pharmacy, Chapel Hill, NC, USA.
Alain ValdiviaDivision of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina-Chapel Hill School of Pharmacy, Chapel Hill, NC, USA.
Lee M GravesDepartment of Pharmacology, University of North Carolina-Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Shawn D HingtgenNeuroscience Center, University of North Carolina-Chapel Hill School of Medicine, Chapel Hill, NC, USA.

Funding

CANCER CELL BIOLOGY TRAINING PROGRAMT32CA071341 · UNIV OF NORTH CAROLINA CHAPEL HILL · 1996 to 2025
$1.1M
NCATS NIH HHS U01 TR003715NCI NIH HHS T32 CA071341
6 · The paper itself

Abstract

Tumor-homing neural stem cell (NSC) therapy is emerging as a promising treatment for aggressive cancers of the brain. Despite their success, developing tumor-homing NSC therapy therapies that maintain durable tumor suppression remains a challenge. Herein, we report a synergistic combination regimen where the novel small molecule TR-107 augments NSC-tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) therapy (hiNeuroS-TRAIL) in models of the incurable brain cancer glioblastoma (GBM)

Indexed as

apoptosisglioblastomaMT: Regular IssueTNF-related apoptosis inducing ligandTR-107TRAILTRAIL resistance

Identifiers

PMID39045029
PMCPMC11263637

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.